Inhibiting JNK activity with SP600125 leads to regression of B-lymphoma growth in vivo. (A) Splenocyte numbers of mice treated with vehicle (DMSO) or drug (SP600125). Mice were administered 10 × 10⁶ BKS-2 B-lymphoma cells on day 0 and subsequently with intraperitoneal injection of 40 mg/kg body weight of the drug SP600125 or the vehicle (DMSO) alternate days for 10 days. Experiments (Expt.) were performed 2 times. (B) Photograph of vehicle- and drug-treated spleen of CBA/N mice on day 11. Horizontal bars represent means of all the numbers for all the mice in the group.